As CAR-T and other cell therapies revolutionize cancer treatment, their potential for tackling neurological disorders like Alzheimer's, Parkinson's, ALS, and MS is sparking new excitement. These innovative therapies could dramatically change the treatment landscape, offering hope to millions of patients worldwide.

The inaugural Cell Therapy for Neurological Disorders Summit is the first industry-focused event dedicated to exploring the latest advancements in cell therapies for neurological disorders. Join leading experts from companies like Aspen Neuroscience, Coya Therapeutics, and Neurona Therapeutics as they share cutting-edge developments in CAR-T, Treg, stem cell-based therapies, and more. Whether you're actively engaged in this groundbreaking work or looking to enter the field, this is your chance to connect with a global network of industry and academic thought leaders and drive innovation in neurological care.

Join us this December to learn from fellow experts looking to bring genuine solutions to patients suffering from neurological disorders.


URLs:
Tickets: https://go.evvnt.com/2624486-2?pid=91 
Brochure: https://go.evvnt.com/2624486-3?pid=91

Prices:
Drug Developer Pricing - Conference + 2 Workshops: USD 4197.00,
Drug Developer Pricing - Conference + 1 Workshop: USD 3598.00,
Drug Developer Pricing - Conference Only: USD 2999.00,
Start-Up/Academic Pricing - Conference + 2 Workshops: USD 3597.00,
Start-Up/Academic Pricing - Conference + 1 Workshop: USD 3098.00,
Start-Up/Academic Pricing - Conference Only: USD 2599.00,
Service Provider Pricing - Conference + 2 Workshops: USD 5097.00,
Service Provider Pricing - Conference + 1 Workshop: USD 4398.00,
Service Provider Pricing - Conference Only: USD 3699.00

Speakers: Ana Sousa, Chief Regulatory Officer and Senior Vice President - Global Regulatory Affairs, Quality and Product Strategy, Aspen Neuroscience, Brian Culley, Chief Executive Officer, Lineage Cell Therapeutics Inc., Fred Grossman, President and Chief Medical Officer, Coya Therapeutics, Howard Federoff, Chief Medical Officer, Kenai Therapeutics, Igor Lavrov, Assistant Professor - Neurology and Biomedical Engineering, Mayo Clinic, Jacob Koffler, Assistant Professor, UCSD, Jeanne Loring, Professor, The Scripps Research Institute, Jim Musick, CSO and Director, Vitro Biopharma, Lucho Fuentealba, Associate Director - Preclinical Discovery, Neurona Therapeutics, Mark Tuszynski, Professor, UCSD, Paul Bradshaw, Chief Executive Officer, Inteligex Inc., Paul Song, Chief Executive Officer and Chairman, NKGen Biotech, Xiaokui Zhang, Chief Scientific Officer, Aspen Neuroscience, Yu-Jen Chang, Senior Engineer - Quality Assurance and Board Product Team Lead, Super Micro Computer Inc., Yves Maury, Director - Discovery department, Neurona Therapeutics